Shows / TheBrief.Health
Episodes
- TheBrief.Health
FDA Class I Recall Targets Medline Kits Containing Recalled BD ChloraPrep Applicators
FDA classified Medline convenience kits containing BD ChloraPrep applicators as Class I due to fungal contamination risks, prompting quarantine, exposure…
- TheBrief.Health
Dostarlimab Opens Treatment-Only Path in Rectal Cancer
FDA granted accelerated approval to dostarlimab for untreated MSI-H or dMMR locally advanced rectal cancer, offering eligible patients potential organ…
- TheBrief.Health
FDA Class I Recall Targets Convenience Kits With Potentially Nonsterile Saline Flush Ampules
FDA classified a recall of convenience kits containing potentially nonsterile saline flush ampules as Class I, warning of serious infection, sepsis…
- TheBrief.Health
Rectal Cancer: Who Fits the Dostarlimab Approval
FDA granted accelerated approval to dostarlimab for untreated stage II or III MSI-H or dMMR rectal cancer, highlighting early biomarker testing and potential…
- TheBrief.Health
FDA Adds Boxed Warning for Symptomatic Hypophosphatemia With Ferric Carboxymaltose
FDA added a boxed warning for ferric carboxymaltose due to severe, prolonged hypophosphatemia, emphasizing patient risk assessment, symptom education…
- TheBrief.Health
Par Health Recalls Two Lots of Premixed Dexmedetomidine After Particulate Matter Is Found
Par Health recalled two dexmedetomidine injection lots after particulate contamination was identified, prompting healthcare facilities to quarantine affected…
- TheBrief.Health
AVID Medical Kits Require Class I Saline Quarantine
FDA classified AVID Medical’s correction of convenience kits containing Huons sodium chloride ampules as Class I, prompting quarantine, exposure tracing, and…
- TheBrief.Health
Atezolizumab Approved for Stage III dMMR Colon Cancer
FDA approved atezolizumab plus chemotherapy after surgery for stage III mismatch-repair-deficient colon cancer, improving three-year disease-free survival and…
- TheBrief.Health
Imlunestrant Makes ESR1 Testing Actionable in Breast Cancer
FDA approved imlunestrant plus abemaciclib for ESR1-mutated advanced breast cancer after endocrine progression, making biomarker testing central to treatment…
- TheBrief.Health
Bravo CF Recall Requires Removal From Esophageal Testing
FDA classified the Bravo CF delivery-device recall as Class I, prompting facilities to quarantine affected inventory, review scheduled procedures, and arrange…
- TheBrief.Health
Tucatinib Maintenance Approval Needs Source Verification
Tucatinib maintenance approval with trastuzumab and pertuzumab remains unverified in the supplied FDA source, requiring confirmation of eligibility, efficacy…
- TheBrief.Health
Bravo CF pH Device Recall Follows 184 Serious Injuries
FDA classified Bravo CF delivery device removal as Class I after 184 serious injuries, prompting inventory verification, procedure reviews, patient assessment…
- TheBrief.Health
Impella Introducer Correction Highlights Major Bleeding Risk
FDA classified the Impella introducer correction as Class I following serious bleeding complaints and deaths, prompting inventory checks, heightened hemorrhage…
- TheBrief.Health
FDA Class I Recall: Aspergillus Contamination in IV-Start and Convenience Kits
FDA warned of fungal contamination in certain IV-start kits, prompting facilities to quarantine affected products, trace patient exposures, and assess…
- TheBrief.Health
Psilocybin May Ease Treatment-Resistant Depression
A randomized study found psilocybin-assisted therapy reduced treatment-resistant depression symptoms through six weeks, supporting further research while…
- TheBrief.Health
FDA Alert: Recall of Glutathione, Myers’ Cocktail and Tri-Immune Boost Injections
FDA recalled six lots of compounded glutathione, Myers’ Cocktail, and Tri-Immune Boost injections over elevated endotoxin levels, prompting quarantine…
- TheBrief.Health
SGLT2 Inhibitors vs GLP-1 Receptor Agonists: What Cardiovascular Evidence Shows
A 2026 network meta-analysis found SGLT2 inhibitors more consistently reduced heart failure hospitalization, while mortality comparisons remained uncertain and…
- TheBrief.Health
FDA Approves First Treatment for MCT8 Deficiency
FDA approved tiratricol for peripheral thyrotoxicosis in MCT8 deficiency, targeting excess T3 and cardiovascular effects without establishing reversal of…
- TheBrief.Health
WHO Moves to Expand Access to Lifesaving Sickle Cell Treatment and Care for Children
WHO’s pediatric sickle cell initiative emphasizes implementation, linking early screening, preventive treatment, referral, medicine access, and follow-up to…
- TheBrief.Health
Baxter Recalls One Lot of Cefazolin in Dextrose Injection After Cardboard Particles Found
Baxter recalled one cefazolin in dextrose injection lot over cardboard particles, prompting hospitals to quarantine affected inventory, maintain perioperative…
- TheBrief.Health
Orforglipron Added to Insulin Glargine Improves HbA1c and Weight in Type 2 Diabetes
ACHIEVE-5 found oral orforglipron added to titrated insulin glargine improved HbA1c and weight without increasing hypoglycemia, though numerical effect sizes…
- TheBrief.Health
Ecopipam Shows Promise for Tourette Syndrome in Young People
A randomized pediatric trial found ecopipam reduced Tourette syndrome tic severity versus placebo, supporting further investigation while long-term safety…
- TheBrief.Health
Luna G3 APAP Recall Targets 20,000-Plus US Devices
FDA classified the Luna G3 APAP firmware recall as Class I, urging clinics and suppliers to verify affected devices, coordinate corrections, and prevent…
- TheBrief.Health
Camizestrant Links ESR1 Detection to Breast Cancer Care
FDA approved camizestrant for eligible ESR1-mutated advanced breast cancer, enabling mutation-guided endocrine switching before radiographic progression while…
- TheBrief.Health
Halyard IV Start Kit Class I Recall Requires Fast Action
FDA classified Halyard IV START KIT NONSTERILE as Class I, prompting urgent inventory isolation, identifier verification, workflow protection, alternative…
- TheBrief.Health
PiCardia ShortCut Recall Flags Positioning-Arm Risk
FDA classified PiCardia’s ShortCut transfemoral catheter action as a Class 2 recall, prompting inventory checks, procedure planning updates, traceability, and…
- TheBrief.Health
Sevabertinib Approved for HER2-Mutant Nonsquamous NSCLC
FDA accelerated approval makes sevabertinib available for previously treated advanced nonsquamous NSCLC with qualifying HER2 mutations, emphasizing precise…
- TheBrief.Health
Lirafugratinib Expands FGFR2 Cholangiocarcinoma Options
FDA approved lirafugratinib for previously treated advanced FGFR2-rearranged cholangiocarcinoma, making validated molecular testing essential for identifying…
- TheBrief.Health
Papaverine Injection Recall Raises Particulate Risk
American Regent recalled a papaverine injection lot after particulate matter findings, prompting quarantine, inventory tracing, exposure assessment, symptom…
- TheBrief.Health
Sevabertinib Approved for Advanced Non-Squamous NSCLC
FDA granted accelerated approval to sevabertinib for select HER2-mutated non-squamous NSCLC, requiring precise molecular eligibility while confirmatory studies…
- TheBrief.Health
Gastric Cancer EFS Improves With Perioperative Serplulimab
ASTRUM-006 found serplulimab plus perioperative SOX improved event-free survival in PD-L1-selected resectable gastric or gastroesophageal junction cancer…
- TheBrief.Health
Recurrent C. Difficile Outcomes Favor FMT Over Antibiotics
Randomized evidence found fecal microbiota transplantation more effective than vancomycin or fidaxomicin for recurrent C. difficile infection, supporting…
- TheBrief.Health
Heart Failure Definition Update Across Care Settings
The 2026 universal heart failure definition standardizes diagnosis and documentation across care settings, potentially affecting referrals, coding, research…
- TheBrief.Health
Preoperative Anemia: What ITACS Can—and Cannot—Change
ITACS evaluates preoperative intravenous iron for anemia before cardiac surgery, but its supplied citation lacks results needed to determine effects on…
- TheBrief.Health
Central Precocious Puberty: When Brain MRI Is Not Routine
Endocrine Society guidance discourages routine brain MRI for selected children with central precocious puberty, emphasizing neurologic assessment and…
- TheBrief.Health
WHO Calls for Stronger Safety Monitoring as GLP-1 Use Expands
WHO urges stronger safety monitoring as GLP-1 use expands for weight loss, emphasizing appropriate prescribing, product verification, structured follow-up, and…
- TheBrief.Health
Esophageal pH Capsule Alert Signals Procedural Safety Risk
FDA reported 184 serious injuries linked to specified esophageal pH capsule delivery devices, prompting inventory review, procedural safeguards, traceability…
- TheBrief.Health
Ebola and Marburg Clinical Care Standards Unified by WHO
WHO’s new filovirus guidance unifies Ebola and Marburg care, emphasizing rapid triage, supportive treatment, infection prevention, staff protection…
- TheBrief.Health
Sacituzumab Tirumotecan Improves PFS in Advanced NSCLC
A phase 3 trial found sacituzumab tirumotecan plus pembrolizumab improved progression-free outcomes in first-line PD-L1-positive advanced NSCLC, while survival…
- TheBrief.Health
Sevabertinib Approval Narrows HER2-Mutated NSCLC Use
FDA cleared Dexcom Stelo for over-the-counter use in people aged 2 years and older without insulin use, expanding access while leaving clinical outcomes…
- TheBrief.Health
Dexcom Stelo Is First OTC Glucose Monitor for Children
FDA cleared Dexcom Stelo for over-the-counter use in people aged 2 years and older without insulin use, expanding access while leaving clinical outcomes…
- TheBrief.Health
Morphine Recall Tests Controlled-Drug Response Readiness
FDA recalled one lot of morphine injection after a label mix-up could expose patients to hydromorphone, requiring rapid stop-use, quarantine, verification, and…
- TheBrief.Health
IV Fosphenytoin for Acute Trigeminal Neuralgia: What the Phase 3 Trial Means for Rescue Care
A randomized phase 3 trial supports intravenous fosphenytoin for rapid relief of severe trigeminal neuralgia, emphasizing monitored rescue use rather than…
- TheBrief.Health
FDA Approves RefluxStop for GERD With Five-Year Post-Approval Study
FDA approved RefluxStop for GERD while requiring five-year follow-up of 200 patients, emphasizing the need to monitor durability, delayed complications, and…
- TheBrief.Health
Semaglutide and Cardiovascular Risk: What a 2026 Meta-Analysis Shows
A 2026 meta-analysis found 32% lower odds of major cardiovascular events with semaglutide, reinforcing cardiovascular benefit while emphasizing baseline risk…
- TheBrief.Health
Low-Dose Naltrexone Remains Unproven for Long COVID
A 2026 systematic review found low-certainty evidence that low-dose naltrexone may improve long COVID symptoms, but uncontrolled studies cannot establish…
- TheBrief.Health
Retatrutide Monotherapy in Early Type 2 Diabetes: Glycemic Control and Weight Loss
Retatrutide monotherapy substantially reduced A1C and body weight in early type 2 diabetes, highlighting triple-receptor agonism while leaving comparative…
- TheBrief.Health
Antimicrobial Resistance Guidance Updates Treatment Choices
IDSA’s 2026 antimicrobial resistance guidance emphasizes mechanism-based treatment, accurate susceptibility testing, source control, and reassessment of…
- TheBrief.Health
ATTR-CM Symptoms and Hospitalizations Improve With Acoramidis
Acoramidis preserved health status and reduced cardiovascular hospitalizations in transthyretin amyloid cardiomyopathy, supporting treatment decisions that…
- TheBrief.Health
Mortality Evidence for Stopping Statins After Age 75
A randomized trial found statin discontinuation after age 75 was noninferior for three-year mortality in primary prevention, supporting individualized…
- TheBrief.Health
Intrauterine hCG Does Not Improve IVF Live Birth Rates
An individual-patient-data meta-analysis found intrauterine hCG before embryo transfer did not improve clinical pregnancy or live birth, questioning its use as…
- TheBrief.Health
Sevabertinib Makes HER2 Testing Actionable in NSCLC
FDA granted accelerated approval to sevabertinib for advanced nonsquamous NSCLC with activating HER2 kinase-domain mutations, emphasizing accurate biomarker…
- TheBrief.Health
Patient Assessment After Possible Recalled Tyenne Exposure
FDA recall of a tocilizumab-aazg lot over possible glass particles prompts inventory quarantine, exposure verification, symptom assessment, documentation, and…
- TheBrief.Health
Zidesamtinib Offers a Post-TKI Option in ROS1 NSCLC
Zidesamtinib offers a new post-TKI option for ROS1-positive NSCLC, with reported intracranial activity, while accelerated approval leaves clinical benefit…
- TheBrief.Health
Andes Virus Cluster Prompts Cruise Ship Case Protocols
A cruise-linked Andes virus cluster highlights targeted testing, exposure tracking, contact follow-up, and coordinated disembarkation, emphasizing credible…
- TheBrief.Health
Finerenone Benefits Span Blood Pressure in HFmrEF and HFpEF
FINEARTS-HF found finerenone reduced worsening heart failure events and cardiovascular death consistently across baseline blood pressure groups, while…
- TheBrief.Health
Parkinson’s Disease Risks With Bilateral Focused Ultrasound
A 2026 multicenter trial found limited additional motor benefit after second focused ultrasound pallidothalamic lesioning, alongside more persistent adverse…